Skip to content
Search

Latest Stories

RPS to respond to 'call for evidence' on pharmacy professional leadership

The Royal Pharmaceutical Society (RPS) has confirmed it will respond to UK Commission’s ‘call for evidence’ on pharmacy professional leadership.

The commission wants to ensure the professions are well equipped, with a voice to help shape the future, and enabled to develop through sharing and learning from best practice.


The UK Commission on Pharmacy Professional Leadership has been set up by the chief pharmaceutical officers of England, Scotland, Wales and Northern Ireland. It will produce recommendations for the future of pharmacy professional leadership in the UK.

The commission is co-chaired by Nigel Clarke, former chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, professor of medical education at University College London's Medical School.

The commission will be hosting a webinar and has urged the associations and individuals to take part in ‘call for evidence’ which has been launched to inform and develop its work.

A webinar in England will take place on Wednesday 7 September 6:30 – 8 pm. In Scotland it will be organised on Tuesday 6 September 7-8:30 pm and in Wales it will be hosted on Thursday 8 September 7-8:30 pm.

The RPS has welcomed the scrutiny of pharmacy professional leadership and the opportunity presented by the independent commission following a very positive and productive first meeting.

It said: “We will respond to the call for evidence issued by the commission today and will engage across the organisation with our boards and assembly to shape our submission.”

RPS agrees that professional leadership needs to evolve in step with developments in patient needs and service provision. Future professional leadership needs to be independent, proactive, challenging, forward-looking and always with patient benefit as the first consideration.

“We are open to change and evolution. The Assembly recently confirmed it will review RPS governance, following the conclusion of the Independent Commission, to ensure it remains fit for purpose to meet the future vision of professional leadership. The Assembly is also open to reviewing our Royal Charter for the benefit of pharmacy professional leadership and we will involve members in this from the outset,” RPS said.

“We also want to work closely with APTUK and other professional membership bodies across the pharmacy sectors to strengthen pharmacy professional leadership.

“To truly deliver a future vision, pharmacy needs a post-registration model akin to medicine, whereby RPS is awarded delegated authority by the regulator to formally define and assure post-registration standards. This needs to be complemented with the implementation of RPS curricula by employers into career development pathways. The Commission is ideally placed to realise this.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less